Categories:
ANVISA – New Regulatory Framework for Medical Cannabis
The 1st Public Meeting of the Collegiate Board (DICOL) of 2026, held on January 28, was consolidated
Read more
ANVISA – Highlights from the 3rd Dicol Meeting 2026
The 3rd Public Meeting of the Dicol in 2026 reaffirmed ANVISA’s trajectory towards a more tran
Read more
The Digital Modernization of CADIFA and its Evolution in the Brazilian Regulatory Landscape
Within the scope of the recent digital transformation initiatives led by the Brazilian Health Regula
Read more
INFARMED – Mandatory submission of national pharmacovigilance contact details via the SMUH-ALTER Portal
On 30 October 2025, INFARMED published the Informative Circular No. 125/CD/550.20.001, introducing
Read more
Vita participates in a workshop on the advances and challenges of Advanced Therapies in Brazil
Vita attended the workshop “The Journey of Advanced Therapies in Brazil – Advances, Challenges,
Read more
ANVISA – Atualização da RDC 948/2024
A RDC 948/2024, publicada em dezembro de 2025 como novo marco regulatório para registro de medicame
Read more
ICH M4Q(R2): draft revision open for public consultation
As part of the work initiated in 2021 by the International Council Harmonization (ICH), the revision
Read more
A New Era in Medicines Regulation in the European Union (EU): From the artificial intelligence (AI) Strategy to the First AI Observatory Report
In May 2025, the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA – th
Read more
ANVISA – Cadifa Panel Launches!
Anvisa has just launched two extremely useful panels for monitoring the process of Letter of Suitabi
Read more
ANVISA – Publication of the regulation for admissibility of analysis carried out by a Foreign Regulatory Authority (Reliance) in Brazil
In August 2022, ANVISA published the Resolution – RDC No. 741, of August 10, 2022, which provides
Read more
EMA – ICH opens public consultation for international harmonization of real-world evidence terminology
The European Medicines Agency has published for public consultation an ICH Reflection Paper on “Pr
Read more
ANVISA – List of Active Substances for Periodic Benefit-Risk Evaluation Reports (updated on December 20th, 2021)
On December 13th, 2021, ANVISA published the list of Periodic Benefit-Risk Assessment Reports (RPBR)
Read more